The Skimune^® platform (Skimune^®Cosm; Skimune^®Chem; Skimune^®Mab) are unique non-artificial human in vitro skin tests

The Skimune^® platform predicts hypersensitivity responses to pharmaceuticals including small molecule drugs and monoclonal antibodies, chemicals and cosmetics

Skimune^® provides a pre-clinical predictive readout of skin damage which correlates with screening assays ie. cytokine release and T cell proliferation

Skimune^®Mab is the only commercially available test for predicting adverse immune reactions to monoclonal antibodies, biobetters, biosimilars and antibody drug conjugates

The Skimune^® platform tests are also used in dose response and efficacy studies for immunomodulatory drugs prior to Phase One clinical trials

The Skimune^® 3D high throughput screening for the detection of sensitisation and toxicity to drugs, chemicals and cosmetics